CYGNOS BioTech Awarded U.S. Department of Defense SBIR Phase II Contract

Miami, FL – March 23, 2026 — CYGNOS BioTech, LLC is proud to announce that we have officially been awarded a U.S. Department of Defense SBIR Phase II contract, with an effective start date of February 2, 2026.

This award represents a major milestone in advancing our PVX host-directed antiviral biologic platform, building upon the successful completion of SBIR Phase I.

SBIR Phase II execution will focus on:

  • Scalable manufacturing development and advancement of FDA-aligned CMC regulatory compliance.
  • Expanded analytical and structural characterization to support reproducibility and comparability.
  • Prototype-level antiviral validation across priority virus families relevant to biodefense and public health.
  • Regulatory pathway alignment to enable future operational, veterinary, and clinical transition for the human space.

PVX is a virus-agnostic, host-directed biologic platform designed to address current and emerging biological threats of military and public health relevance. By targeting host cellular pathways rather than individual viral proteins, PVX is engineered to preserve functional activity despite viral mutation and evolutionary escape.

Dr. Jay E. Yourist, Co-Founder and President of CYGNOS BioTech, stated:

“The SBIR Phase II award validates both the scientific foundation and strategic relevance of our PVX biologic platform. With Phase II now underway, we are integrating manufacturing scale-up, functional validation, and regulatory planning to advance PVX toward prototype maturity and operational readiness.”

CYGNOS continues to collaborate closely with government, academic, and industry to help position its technology for real‑world adoption by the U.S. Department of Defense, while advancing a long‑term One Health strategy that integrates veterinary and human antiviral development. This approach supports both military readiness and civilian public health by enabling cross‑species solutions to emerging and re‑emerging infectious diseases.

We look forward to executing Phase II activities and delivering scalable biodefense countermeasures in collaboration with Southwest Research Institute (San Antonio, Texas), CUBRC (Buffalo, New York), and QuarryBio (Tallahassee, Florida). These organizations bring expertise in advanced manufacturing, high-containment virology, translational research, and analytical development to support Department of Defense and public health objectives.

For additional information about CYGNOS BioTech and its antiviral development programs, please contact info@cygnosbiotech.com or visit www.cygnosbiotech.com.

Reference to the Department of Defense, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, or any other agency of the United States Government does not constitute or imply endorsement or recommendation by the United States Government or any agency thereof.